LDL particle size and antioxidant HDL function improve after sustained virological response in patients with chronic HCV.

Direct-acting antivirals with or without peginterferon α (PEG-IFN α) plus ribavirin are now available for the treatment of hepatitis C virus (HCV) infection. Direct-acting antivirals are potent inhibitors of HCV replication, but some of them occasionally possess serious adverse events. We experienced a 64-year-old female with chronic HCV genotype 1b infection who showed elevated alanine aminotransferase of 528 IU/l at week 9 after the commencement of treatment of simeprevir with PEG-IFN α-2a plus ribavirin. However, she achieved sustained virological response at week 24 after the end of treatment. In Japan, we also have to treat elderly patients infected with HCV and/or advanced hepatic fibrosis. Until an effective interferon-free regimen is established, direct-acting antivirals with PEG-IFN plus ribavirin may still play a role in the treatment for certain patients. To avoid serious results from adverse events, careful attention and follow-up will be needed in the treatment course of simeprevir with PEG-IFN plus ribavirin for chronic HCV infection.

Download Full-text

Impact of sustained virological response to chronic hepatitic C antiviral therapy on new onset diabetes mellitus type 2 after controlling for metabolic syndrome

Journal of Investigative Medicine ◽

10.1136/jim-2016-000343 ◽

2017 ◽

Vol 65 (4) ◽

pp. 765-771 ◽

Cited By ~ 7

Author(s):

Prashant Pandya ◽

Chaitanya Pant ◽

Ryan Taylor ◽

Olurinde Oni

Keyword(s):

Diabetes Mellitus ◽

Metabolic Syndrome ◽

Sustained Virological Response ◽

Virological Response ◽

Hcv Infection ◽

History Of ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

New Onset

The high cost associated with antiviral treatment for chronic hepatitis C virus (HCV) infection mandates further investigation in the context of preventing complications such as type 2 diabetes mellitus (DM2). We determined the cumulative incidence of DM2 in subjects with chronic HCV infection who received concomitant pegylated interferon (Peg-IFN) and ribavirin. We conducted a retrospective analysis of data obtained from Veterans Administrations Informatics and Computing Infrastructure (VINCI) to identify an adult cohort of patients without diabetes with chronic HCV infection who received Peg-IFN-based therapy between October 2001 and December 2011. Patients with history of HIV, hepatitis B infection, hepatocellular cancer (HCC), non-HCC cancers, and history of transplantation were excluded. Sustained virological response (SVR) was defined as negative HCV RNA 3 months after completion of therapy. Using Cox proportional hazards regression for multivariable analysis, we determined that patients who achieved SVR were at a significantly less risk of developing DM2. Adjusted survival rates showed that the responders' group was significantly less likely to develop DM2 over time (HR 0.60, CI 0.48 to 0.74, p<0.001). Peg-IFN-based therapy in chronic HCV patients that resulted in SVR significantly decreased the risk of developing DM2 and independently predicts the development of new onset disease after controlling for correlates of metabolic syndrome.

Download Full-text

IL28B genetic variations are associated with high sustained virological response (SVR) of interferon-α plus ribavirin therapy in Taiwanese chronic HCV infection

Genes and Immunity ◽

10.1038/gene.2011.1 ◽

2011 ◽

Vol 12 (4) ◽

pp. 300-309 ◽

Cited By ~ 37

Author(s):

J-Y Chen ◽

C-Y Lin ◽

C-M Wang ◽

Y-T Lin ◽

S-N Kuo ◽

...

Keyword(s):

Sustained Virological Response ◽

Virological Response ◽

Genetic Variations ◽

Hcv Infection ◽

Interferon Α ◽

Chronic Hcv Infection ◽

Chronic Hcv ◽

High Sustained Virological Response

Download Full-text

Response of Ns5a inhibitors resistant patients to Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy for chronic hepatitis c virus infection

QJM ◽

10.1093/qjmed/hcab100.139 ◽

2021 ◽

Vol 114 (Supplement_1) ◽

Author(s):

Ahmed A Moanes ◽

Hesham H Radwan ◽

Yasser O Abd El Rahman ◽

Mostafa M Abd El Nabi

Keyword(s):

Chronic Hepatitis ◽

Hepatitis C Virus ◽

Hepatitis C ◽

Sustained Virological Response ◽

Chronic Hepatitis C ◽

Virological Response ◽

Hcv Treatment ◽

Number Of Patients ◽

Chronic Hepatitis C Virus ◽

Chronic Hcv

Abstract Background Hepatitis C Virus (HCV) infection is a major global health challenge; it is estimated that more than 80 million people are chronically infected worldwide, with 3–4 million new infections and 350 000 deaths occurring each year because of HCV-related complications. Aim of the work to determine the efficacy of Qurevo-Sovaldi-Ribavirin regimen as a retreatment strategy in NS5A inhibitors (Sofosbuvir & Daclatasvir) resistant patients infected with chronic hepatitis C virus. Patients and Methods An observational cross-sectional study was carried out on 20 chronic hepatitis C virus infected patients in The centre of HCV treatment at El Quabary specialized centers in Alexandria where large number of patients receiving their HCV treatment. Results all patients (20/20) achieved sustained virological response after 3 months of the last dose of treatment (SVR12). Conclusion the new retreatment strategy composed of the triple therapy Qurevo (Ombitasvir/Paritaprevir/Ritonavir)/Sofosbuvir/Ribavirin is effective in the treatment of chronic HCV infected patients previously treated with Sofosbuvir/Daclatasvir/Ribavirin for 12 weeks without achieving sustained virological response (Ns5a inhibitors resistant chronic HCV patients).

Download Full-text

Plasma Interferon-Gamma-Inducible Protein-10 Levels Are Associated with Early, but Not Sustained Virological Response during Treatment of Acute or Early Chronic HCV Infection

PLoS ONE ◽

10.1371/journal.pone.0080003 ◽

2013 ◽

Vol 8 (11) ◽

pp. e80003 ◽

Cited By ~ 8

Author(s):

Jordan J. Feld ◽

Jason Grebely ◽

Gail V. Matthews ◽

Tanya Applegate ◽

Margaret Hellard ◽

...

Keyword(s):

Sustained Virological Response ◽

Interferon Gamma ◽

Virological Response ◽

Hcv Infection ◽

Chronic Hcv Infection ◽

Inducible Protein ◽

Chronic Hcv

Download Full-text

The effect of sustained virological response on the risk of extrahepatic manifestations of hepatitis C virus infection

Gut ◽

10.1136/gutjnl-2017-313983 ◽

2017 ◽

Vol 67 (3) ◽

pp. 553-561 ◽

Cited By ~ 57

Author(s):

Parag Mahale ◽

Eric A Engels ◽

Ruosha Li ◽

Harrys A Torres ◽

Lu-Yu Hwang ◽

...

Keyword(s):

Sustained Virological Response ◽

Virological Response ◽

Cox Regression ◽

Porphyria Cutanea Tarda ◽

Hcv Infection ◽

Hcv Rna ◽

Extrahepatic Manifestations ◽

Mixed Cryoglobulinaemia ◽

Using Data ◽

Chronic Hcv

Background and aimChronic HCV infection is associated with several extrahepatic manifestations (EHMs). Data on the effect of sustained virological response (SVR) on the risk of EHMs are limited.MethodsWe conducted a retrospective cohort study using data of patients from the US Veterans Affairs HCV Clinical Case Registry who had a positive HCV RNA test (10/1999-08/2009). Patients receiving interferon-based antiviral therapy (AVT) were identified. SVR was defined as negative HCV RNA at least 12 weeks after end of AVT. Risks of eight incident EHMs were evaluated in Cox regression models.ResultsOf the 160 875 HCV-infected veterans, 31 143 (19.4%) received AVT, of whom 10 575 (33.9%) experienced SVR. EHM risk was reduced in the SVR group compared with untreated patients for mixed cryoglobulinaemia (adjusted HR (aHR)=0.61; 95% CI 0.39 to 0.94), glomerulonephritis (aHR=0.62; 95% CI 0.48 to 0.79), porphyria cutanea tarda (PCT) (aHR=0.41; 95% CI 0.20 to 0.83), non-Hodgkin’s lymphoma (NHL) (aHR=0.64; 95% CI 0.43 to 0.95), diabetes (aHR=0.82; 95% CI 0.76 to 0.88) and stroke (aHR=0.84; 95% CI 0.74 to 0.94), but not for lichen planus (aHR=1.11; 95% CI 0.78 to 1.56) or coronary heart disease (aHR=1.12; 95% CI 0.81 to 1.56). Risk reductions were also observed when patients with SVR were compared with treated patients without SVR for mixed cryoglobulinaemia, glomerulonephritis, PCT and diabetes. Significant reductions in the magnitude of aHRs towards the null with increasing time to initiation of AVT after HCV diagnosis were observed for glomerulonephritis, NHL and stroke.ConclusionsRisks of several EHMs of HCV infection are reduced after AVT with SVR. However, early initiation of AVT may be required to reduce the risk of glomerulonephritis, NHL and stroke.

Download Full-text